REGENERON PHARMACEUTICALS, INC. · Drugmakers

REGN

Low riskNext report: Around Jan 11, 2027 (est.)

View price ↗

The short version

A high-quality, profitable business with growing sales.

Going well

Sales up 17% in the latest quarter vs a year ago
Profitable every year for 10 years
Brings in more cash than it spends

Money moves

Insiders sold $3.2M in the last 30 days, all through pre-planned sales
Institutions added 4.2% to their holdings in the quarter ending June 2026 (592 bought, 699 sold)
Held by Ray Dalio (Bridgewater)

Facts from SEC filings, not a recommendation.

What the price means

Price as of Oct 26

$807.57+0.3% that day

Company value: $75.9B; Share price times all shares
Price vs profit (P/E): 20.0x; You pay about $20 for each $1 of yearly profit
Price vs sales: 4.9x; Company value is 4.9 times a year of sales
Cash vs value: 3%; Cash as a share of company value
Debt vs value: 3%; Debt as a share of company value

From REGN's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.

The business over time

Last 12 quarters, from SEC filings

Sales, Jun '26

$4.3B+17% vs a year earlier

Sep '23Tap a barJun '26

Last 12 months: $15.5B, up 9.3% from the 12 months before. Over 5 years, sales grew about 11% a year.

What the price assumes

Your guesses, our math

Move the sliders to your own view of REGN. Starting points are the company's recent numbers.

Sales growth+9% a yearRecently: +9.3% a yearProfit margin28%Last 12 months: 27.9%P/E at the end20xToday: 20.0x. Many steady companies trade at 12x to 25xShare count change-1% a yearBelow zero means buybacks; above zero means new shares (dilution)

Sales in 5 years$23.9B

Profit in 5 years$6.7B

Price these guesses point to$1,498.05+86% vs $807.57 todayAbout +13% a year, before dividends

What today's price needs: with a 28% margin and a 20x P/E, sales could shrink about 3.7% a year for 5 years and still match today's price.

Simple math on your guesses, not a forecast or a price target. Real results depend on many things these sliders leave out.

Price

Price chart by TradingView.

Business quality

The checklist Warren Buffett-style investors use. Annual numbers for 2025.

5/6Strong

MissReturn on equity 15%+Earns a lot on the money owners have in the business.14.9%
PassDebt under half of equityNot relying on borrowed money.0.06x equity
PassNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.31.4%
PassProfitable every yearSteady profits, not one good year.10 of 10 years
PassFree cash flow positiveBrings in more cash than it spends to run and grow.$5.0B
PassShare count not growingNot diluting owners. Falling means buybacks.-4.3% in 3 years

Revenue: $14.3B; +1.0% vs prior year
5-year growth: +11.0%/yr; revenue, per year
Total debt: $2.0B; 0.06x equity
Current ratio: 4.13x; short-term assets / bills due

From annual reports filed with the SEC. Not in this company's SEC data, so not scored: gross margin 40%+. A checklist is a starting point for research, not a verdict.

Latest quarter

Quarter ended Jun 30, 2026

Reported Oct 6

Revenue: $4.3B; +16.7% YoY
EPS: $12.23; vs $12.81
Op. margin: 30.1%; +0.7 pts
Free cash flow: $572.8M
Share count: -2.4%; vs a year ago

Insider rating

Last 90 days

44Mixed

Pre-planned sales of $3.2M (weaker signal)

50 is neutral. Buying by more insiders, top executives and bigger stakes raises it. Selling lowers it; pre-planned sales count less.

Weekly insider trend

13 weeks agoBoughtSoldThis week

Filing buzz

Last 7 days vs normal

0/ 100

This week: 0
Normal week: 1.5
vs normal: 0.0x

SEC filings of any kind. 50 means a normal week.

Institutional ownership

Steady+4.2%

Institutions added 4.2% to their holdings. 592 bought, 699 sold.

Shares held by institutions91.6M

Sep '24Jun '26

Safety check

From SEC filings

Share count growthYearly rate, last 3 years

-1.5%

Cash runwayAt last year's cash burn

Cash flow positive

Debt to equityLatest balance sheet: debt compared with what owners have

0.1x · $2.0B debt

Shares outstandingLatest reported

94M

Earnings reports

Last 12

Next reportAround Jan 11, 2027 (est.)Estimated from the same quarter last year

Results filedOct 6
Results filedJul 30
Results filedJul 6
Results filedApr 29
Results filedApr 8

Flags and big holders

Offerings 6 months, flags 12 months, holders 90 days

No offerings, red flags or new big holders. Clean record.

Insider trades

Open-market buys and sells, last 90 days

Bought$00 insiders

Sold$3.2M1 insider, 1 pre-planned

Insider	Trade	Shares	Avg price	Value	Owns after	Date
Andrew J MurphyCo-Chief Scientific Officer	Sell	4K	$772.70	$3.2M	48K	Oct 14Filing ↗
-8% of their holdings $753.76 to $781.47 across 27 trades Pre-planned sale (10b5-1) Filed 1 day after